Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

被引：0
作者：
Hu, Bei [1 ]
Korsos, Victoria [2 ]
Palomba, M. Lia [2 ,3 ]
机构：
[1] Wake Forest Sch Med, Atrium Hlth Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC 28202 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapy Serv, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词：
chimeric antigen receptor T cell therapy (CAR T cell therapy); diffuse large B cell lymphoma (DLBCL); high grade B cell lymphoma; mantle cell lymphoma (MCL); relapsed and refractory lymphoma; CENTRAL-NERVOUS-SYSTEM; AXICABTAGENE CILOLEUCEL; COST-EFFECTIVENESS; BREXUCABTAGENE AUTOLEUCEL; PREDICTIVE FACTORS; OUTCOMES; MULTICENTER; INFLAMMATION; PERSISTENCE; IBRUTINIB;
D O I：
10.3389/fonc.2024.1394057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.
引用
收藏
页数：13
相关论文
共 102 条
  • [81] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph P.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason R.
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, S. Ronan
    Ho, P. Joy p
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Pantano, Serafino
    Pacaud, Lida B.
    Awasthi, Rakesh
    Chu, Jufen
    Anak, Ozlem
    Salles, Gilles
    Maziarz, Richard T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) : 45 - 56
  • [82] Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
    Sehgal, Alison
    Hoda, Daanish
    Riedell, Peter A.
    Ghosh, Nilanjan
    Hamadani, Mehdi
    Hildebrandt, Gerhard C.
    Godwin, John E.
    Reagan, Patrick M.
    Wagner-Johnston, Nina
    Essell, James
    Nath, Rajneesh
    Solomon, Scott R.
    Champion, Rebecca
    Licitra, Edward
    Fanning, Suzanne
    Gupta, Neel
    Dubowy, Ronald
    D'Andrea, Aleco
    Wang, Lei
    Ogasawara, Ken
    Thorpe, Jerill
    Gordon, Leo, I
    [J]. LANCET ONCOLOGY, 2022, 23 (08) : 1066 - 1077
  • [83] CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
    Siddiqi, Tanya
    Wang, Xiuli
    Blanchard, M. Suzette
    Wagner, Jamie R.
    Popplewell, Leslie L.
    Budde, L. Elizabeth
    Stiller, Tracey L.
    Clark, Mary C.
    Lim, Laura
    Vyas, Vibhuti
    Brown, Christine E.
    Forman, Stephen J.
    [J]. BLOOD ADVANCES, 2021, 5 (20) : 4059 - 4063
  • [84] Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
    Sim, Austin J.
    Jain, Michael D.
    Figura, Nicholas B.
    Chavez, Julio C.
    Shah, Bijal D.
    Khimani, Farhad
    Lazaryan, Aleksandr
    Krivenko, Gabriel
    Davila, Marco L.
    Liu, Hien D.
    Falchook, Aaron D.
    Dahiya, Saurabh
    Rapoport, Aaron P.
    Kim, Sungjune
    Locke, Frederick L.
    Robinson, Timothy J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (05): : 1012 - 1021
  • [85] Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States
    Simons, Claire L.
    Malone, Daniel
    Wang, Michael
    Maglinte, Gregory A.
    Inocencio, Tim
    Wade, Sally W.
    Bennison, Craig
    Shah, Bijal
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 421 - 431
  • [86] Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
    Snyder, Sophie
    Chung, Karen C.
    Jun, Monika P.
    Gitlin, Matthew
    [J]. ADVANCES IN THERAPY, 2021, 38 (09) : 4659 - 4674
  • [87] Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
    Turtle, Cameron J.
    Hanafi, Laila-Aicha
    Berger, Carolina
    Hudecek, Michael
    Pender, Barbara
    Robinson, Emily
    Hawkins, Reed
    Chaney, Colette
    Cherian, Sindhu
    Chen, Xueyan
    Soma, Lorinda
    Wood, Brent
    Li, Daniel
    Heimfeld, Shelly
    Riddell, Stanley R.
    Maloney, David G.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (355)
  • [88] Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease
    van Rhee, Frits
    Fayad, Luis
    Voorhees, Peter
    Furman, Richard
    Lonial, Sagar
    Borghaei, Hossein
    Sokol, Lubomir
    Crawford, Julie
    Cornfeld, Mark
    Qi, Ming
    Qin, Xiang
    Herring, Jennifer
    Casper, Corey
    Kurzrock, Razelle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (23) : 3701 - 3708
  • [89] Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
    Verdun, Nicole
    Marks, Peter
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [90] CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
    Vu, Khoan
    Frank, Matthew J.
    [J]. BLOOD ADVANCES, 2023, 7 (03) : 375 - 378
234567891011